A Long-term, Open-label, Non-comparative Study to Evaluate the Safety and Efficacy of a Modigraf Based Immunosuppression Regimen in Paediatric Solid Allograft Recipients
Phase of Trial: Phase IV
Latest Information Update: 13 Dec 2017
At a glance
- Drugs Tacrolimus (Primary)
- Indications Allotransplant rejection; Heart transplant rejection; Liver transplant rejection; Renal transplant rejection
- Focus Adverse reactions; Therapeutic Use
- Acronyms PROGRESSION
- Sponsors Astellas Pharma; Astellas Pharma Europe Ltd
- 12 Dec 2017 This trial was discontinued in France, according to European Clinical Trials Database.
- 08 Dec 2017 Status changed from active, no longer recruiting to discontinued.
- 25 Oct 2017 This study has been discontinued Germany.